


## Certificate of Analysis

**MT-517L**

### Guanosine 3',5'-cyclic phosphate, ammonium salt, [8-<sup>3</sup>H]-



**Lot #:** 393-104-0039-A-20200730-DNG


**Specific Activity:** 3.9 Ci/mmol

**Concentration:** 1.0 mCi/ml; 92.95 µg/ml

**Packaged in:** Ethanol : water (1 : 1) solution

**Date of Analysis:** July 30, 2020

**Radiochemical Purity by HPLC:** 98%



**HPLC ANALYSIS LOT 393-104-0039-A-20200730-DNG**  
File Name: intj30 Date and Time: 7/30/2020 11:51:10 A  
Unit 19 - Radio

Peak #	Area %	Time	Area
1	98.37	5.96670	11298.25594
2	0.15	6.76670	16.95782
3	0.58	7.10330	66.89734
4	0.34	7.49000	38.99102
5	0.05	7.89170	6.31459
6	0.24	19.54670	27.57215
7	0.27	19.93330	30.75719
Totals	100.00		11485.74605

**Stability and Storage Recommendation:** The rate of decomposition is approximately 1%/month for the first six months after purification when stored at -20°C.

**Quality Level Disclaimer:** Results were obtained utilizing non-qualified instrumentation, methods that have not been validated or transferred, and analyses not performed according to a formal, documented, analytical protocol.

When handling this radiochemical, please refer to the safe handling of isotopes document provided with your shipment. If the document is misplaced, a link to a copy is available at [www.moravek.com/customer-service](http://www.moravek.com/customer-service).

In addition to the hazard connected with radiation, this compound also has chemical safety characteristics that need to be taken into account before it can be safely worked with. For assistance with designing a safe working environment and procedures for this and all chemicals at your workplace, please contact OSHA at 800-321-6742(OSHA) or [https://www.osha.gov/html/Feed\\_Back.html](https://www.osha.gov/html/Feed_Back.html).

**Caution:** This material was manufactured under research grade conditions and is intended for investigational or manufacturing use only. It is pharmaceutically unrefined and is not suitable for use in humans or clinical diagnosis. Responsibility for its use and compliance with federal law rests solely with the purchaser. If the compound and/or any associated information/documentation derived from its use could be used for any potential future filings, research grade material is not recommended.